Currently out of the existing stock ratings of Carl Byrnes, 41 are a BUY (82%), 9 are a HOLD (18%).

Carl Byrnes

Work Performance Price Targets & Ratings Chart

Analyst Carl Byrnes, currently employed at NORTHLAND CAPITAL MARKETS, carries an average stock price target met ratio of 27.93% that have a potential upside of 20.69% achieved within 107 days.

Carl Byrnes’s has documented 96 price targets and ratings displayed on 13 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BLFS, BioLife Solutions at 08-Jan-2025.

Wall Street Analyst Carl Byrnes

Analyst best performing recommendations are on ESPR (ESPERION THERAPEUTICS).
The best stock recommendation documented was for ESPR (ESPERION THERAPEUTICS) at 4/16/2020. The price target of $42 was fulfilled within 21 days with a profit of $6.14 (17.12%) receiving and performance score of 8.15.

Average potential price target upside

of $10.98 (27.37%) on ESPR (ESPERION THERAPEUTICS).
of $10.6 (35.59%) on BLFS (BIOLIFE SOLUTIONS).
of $3.59 (105.65%) on BWAY (BRAINSWAY LTD).

ESPR Esperion Therapeutics FLXN Flexion Therapeutics ADMS Adamas Pharmaceuticals NBRV Nabriva Therapeutics AG PTE Polarityte VTVT vTv Therapeutics ZGNX Zogenix AMRN Amarin PLC ALVO Alvotech ARDS Aridis Pharmaceuticals BLFS BioLife Solutions BWAY Brainsway Ltd MDXG MiMedx Group

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Joseph Pantginis (HC WAINWRIGHT)